Everything below concerns actin-binding fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-24. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
The Combined DNA Index System (CODIS) is a database that the FBI uses to hold genetic profiles of all known felons, misdemeanants, and arrestees. Some people argue that individuals who are using genealogy databases should have an expectation of privacy in their data that is or may be violated by genetic searches by law enforcement. These different services have warning signs about potential third parties using their information, but most individuals do not read the agreement thoroughly. According to a study by Christi Guerrini, Jill Robinson, Devan Petersen, and Amy McGuire, they found that the majority of the people who took the survey support police searches of genetic websites that identify genetic relatives. People who responded to the survey are more supportive of police activities using genetic genealogy when it is for the purpose of identifying offenders of violent crimes, suspects of crimes against children or missing people. The data from the surveys that were given show that individuals are not concerned about police searches using personal genetic data if it is justified. It was found in this study that offenders are disproportionally low-income and black and the average person of genetic testing is wealthy and white. The results from the study had different results. In 2016, there was a survey called the National Crime Victimization Survey (NCVS) that was provided by the US Bureau of Justice Statistics. In that survey, it was found that 1.3% of people aged 12 or older were victims of violent crimes, and 8.85 of households were victims of property crimes.
While clarifying he was "not a harsh critic of games", Antonov felt "artists and art directors should make their own life a little bit harder by pushing management to take more artistic risks, and use [their] technology [at] a better, higher level".
==== Illicit drugs ==== The sources and production mechanisms of illegal drugs has been another area that has seen successful application of hydrogen isotope characterization. Usually, as with other applications of stable isotope techniques, results are best when data for multiple stable isotopes are compared with one another. δ2H, δ13C and δ15N have been used together to analyze tablets of MDA and MDMA and has successfully identified differences which could be used to differentiate between different sources or production mechanisms. The same combination of stable isotopes with the addition of δ18O was applied to heroin and associated packaging and could successfully distinguish between different samples. Analysis using deuterium NMR was also able to shed light on the origin and processing of both cocaine and heroin. In the case of heroin this site-specific natural isotopic fraction measured by deuterium NMR (SNIF-NMR) method could be used for determining the geographic origin of the molecule by analyzing so-called natural sites (which were present in the morphine from which heroin is made), as well as gaining information on the synthesis process by analyzing the artificial sites (added during drug processing).
=== Forms === Because of its chemical stability, pyridoxine hydrochloride is the form most commonly given as vitamin B6 dietary supplement. Absorbed pyridoxine (PN) is converted to pyridoxamine 5'-phosphate (PMP) by the enzyme pyridoxal kinase, with PMP further converted to pyridoxal 5'-phosphate (PLP), the metabolically active form, by the enzymes pyridoxamine-phosphate transaminase or pyridoxine 5'-phosphate oxidase, the latter of which also catalyzes the conversion of pyridoxine 5′-phosphate (PNP) to PLP. Pyridoxine 5'-phosphate oxidase is dependent on flavin mononucleotide (FMN) as a cofactor produced from riboflavin (vitamin B2). For degradation, in a non-reversible reaction, PLP is catabolized to 4-pyridoxic acid, which is excreted in urine.
=== Home media === Following its cinematic release in the late 1980s, the film was released to television in a syndicated two-night broadcast. Extra footage was added to the film to fill in the block of time. The film was later released in VHS video format on 5 May 1998. The Region 1 widescreen edition of the film was released on DVD in the United States on 23 February 1999. Special features for the DVD include: production notes, cast and filmmakers' biographies, film highlights, web links, and the theatrical cinematic. It was released on Blu-ray Disc by Umbrella Entertainment in Australia in 2019, and in 2020 by Kino Lorber in the US. It is also available in other media formats such as video on demand.
Sources: en.wikipedia.org
== Production process == Single-cell proteins develop when microbes ferment waste materials (including wood, straw, cannery and food-processing wastes, residues from alcohol production, hydrocarbons, or human and animal excreta). With 'electric food' processes the inputs are electricity, CO2 and trace minerals and chemicals such as fertiliser. It is also possible to derive SCP from natural gas to use as a resilient food. Similarly SCP can be derived from waste plastic by upcycling. The problem with extracting single-cell proteins from waste products is the dilution and cost. They are found in very low concentrations, usually less than 5%. Engineers have developed ways to increase the concentrations including centrifugation, flotation, precipitation, coagulation, and filtration, or the use of semi-permeable membranes. The single-cell protein must be dehydrated to approximately 10% moisture content and/or acidified to aid in storage and prevent spoilage. The methods to increase the concentrations to adequate levels and the de-watering process require equipment that is expensive and not always suitable for small-scale operations. It is economically prudent to feed the product locally and soon after it is produced.
== Corporate governance == As of July 2026, Biocon remains chaired by Mazumdar-Shaw. Effective 1 April 2026, Shreehas Tambe was appointed Chief Executive Officer and Managing Director of Biocon Limited—the first CEO of the integrated company following the full integration of Biocon Biologics Limited as a wholly owned subsidiary; Kedar Upadhye was appointed Chief Financial Officer. Tambe succeeded Siddharth Mittal, who resigned effective 31 March 2026 and moved to another leadership role within the Biocon Group. Mittal had led the company since December 2019, when he replaced CEO and Managing Director Arun Chandavarkar. In 2021, Christiane Hamacher resigned as CEO of Biocon Biologics India Limited, following differences with Mazumdar-Shaw. Hamacher had been appointed to that role in March 2019.
=== Sponges (Porifera) === Sponges are some of Earth’s oldest and most ubiquitous animals. The appearance of sponge spicule fossils date back to the Precambrian Era around 580 million years ago. An assemblage of these fossils were found in the Doushanto formation in Southern China. Some circular impressions from the Ediacaran Hills in Southern Australia are also reported to be sponges. They are one of the only lineages of metazoans from this era that continue to survive, and remain relatively unchanged. Sponges are such successful organisms due to their simple, yet effective morphology. They do not possess mouths or any digestive, nervous or circulatory systems. Instead they are filter feeders, which means that they obtain food through nutrients in the water. They have pores, called ostia, that water travels through to a chamber called the spongocoel, and exits through a chamber called the osculum. Through this water filtration system, they obtain nutrients that are needed for their survival. Specifically, they intracellularly digest bacteria, micro-algae or colloids. Sponge skeletons consist of either spongin or calcareous and siliceous spicules with some collagen molecules interspersed. The collagen holds the sponge cells together. Different lineages of sponges are distinguished based on the composition of their skeletons. The three main classes of sponges are Demospongiae, Hexactinellid, and Calcareous. Demonsponges are the most well-known type of sponge since they are used by humans.
The quadriplegia dissipates once the patient lies supine. An extremely rare complication of sCSFL is third nerve palsy, where the ability to move one's eyes becomes difficult and interrupted due to compression of the third cranial nerve. There are documented cases of reversible frontotemporal dementia and coma. Coma due to a CSF leak has been successfully treated by using blood patches and/or fibrin glue and placing the person in the Trendelenburg position. Empty sella syndrome, a bony structure that surround the pituitary gland, occurs in CSF leak patients.
=== Formulations === Available dosage forms include liquids, syrups, drops, elixirs, effervescent tablets, and powders for mixing with water, capsules, tablets including extended-release formulations, suppositories, compounding powder, and injections.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.